Silvercrest Asset Management Group LLC Grows Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Silvercrest Asset Management Group LLC raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 35.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,428 shares of the company’s stock after acquiring an additional 29,182 shares during the period. Silvercrest Asset Management Group LLC owned approximately 0.23% of Amphastar Pharmaceuticals worth $4,937,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AMPH. TD Asset Management Inc lifted its holdings in shares of Amphastar Pharmaceuticals by 449.0% during the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock valued at $49,082,000 after purchasing an additional 649,001 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 348.7% during the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock valued at $36,648,000 after purchasing an additional 460,473 shares in the last quarter. Boone Capital Management LLC bought a new position in Amphastar Pharmaceuticals in the fourth quarter valued at about $24,740,000. Victory Capital Management Inc. lifted its holdings in Amphastar Pharmaceuticals by 870.9% in the fourth quarter. Victory Capital Management Inc. now owns 237,474 shares of the company’s stock valued at $14,688,000 after acquiring an additional 213,014 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in Amphastar Pharmaceuticals in the first quarter valued at about $6,775,000. 65.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AMPH has been the topic of a number of recent research reports. Piper Sandler reissued an “overweight” rating and issued a $71.00 target price on shares of Amphastar Pharmaceuticals in a report on Thursday, June 27th. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.67.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 3,596 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at approximately $3,851,635.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $41.40, for a total transaction of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares in the company, valued at approximately $3,246,132.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 3,596 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total value of $147,184.28. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $3,851,635.79. The disclosure for this sale can be found here. Insiders sold 7,596 shares of company stock worth $313,544 in the last quarter. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH traded up $1.18 during trading on Tuesday, hitting $43.28. 243,072 shares of the company’s stock were exchanged, compared to its average volume of 412,491. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $67.66. The business’s 50-day simple moving average is $40.51 and its 200 day simple moving average is $44.71. The company has a market cap of $2.12 billion, a price-to-earnings ratio of 14.62, a PEG ratio of 0.75 and a beta of 0.80.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.20. The business had revenue of $171.84 million during the quarter, compared to analysts’ expectations of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. As a group, equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.59 EPS for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.